Loading...
Docoh

Yield10 Bioscience (YTEN)

Yield10 Bioscience, Inc. is an agricultural bioscience company developing crop innovations aligned with trends in global food security, social responsibility, and sustainability. The Company is using its 'Trait Factory,' a differentiated trait gene discovery platform including the 'GRAIN' big data mining trait gene discovery tool as well as the Camelina oilseed 'Fast Field Testing' system, to develop improved Camelina varieties to produce proprietary products, and to produce high value seed traits for the agriculture and food industries. The Company's goals are to efficiently develop and commercialize a high value crop products business based on superior varieties of Camelina for producing feedstock oils, nutritional oils, and PHA bioplastics. As a path toward commercialization of novel traits, Yield10 is pursuing a partnering approach with major agricultural companies to drive new traits into development for canola, soybean, corn, and other commercial crops. Yield10 is headquartered in Woburn, MA and has an Oilseeds Center of Excellence in Saskatoon, Canada.

Company profile

Ticker
YTEN
Exchange
CEO
Oliver Peoples
Employees
Incorporated
Location
Fiscal year end
Former names
METABOLIX INC, METABOLIX, INC.
SEC CIK
Subsidiaries
Yield10 Bioscience Securities Corp. • Metabolix Oilseeds, Inc. ...
IRS number
43158289

YTEN stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

10 Aug 22
28 Sep 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 3.44M 3.44M 3.44M 3.44M 3.44M 3.44M
Cash burn (monthly) (no burn) 1.04M 1.15M 1.07M 846K 843.08K
Cash used (since last report) n/a 3.06M 3.38M 3.15M 2.5M 2.49M
Cash remaining n/a 379.22K 63.67K 291.41K 947.12K 955.73K
Runway (months of cash) n/a 0.4 0.1 0.3 1.1 1.1

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
17 Aug 22 Sinskey Anthony J Common Stock Buy Acquire P No No 2.7996 2,000 5.6K 17,309
16 Aug 22 Sinskey Anthony J Common Stock Buy Acquire P No No 2.849 2,000 5.7K 15,309
15 Aug 22 Sinskey Anthony J Common Stock Buy Acquire P No No 2.765 2,000 5.53K 13,309
10 Aug 22 Haaser Charles B Common Stock Payment of exercise Dispose F No No 2.68 822 2.2K 11,279
10 Aug 22 Snell Kristi Common Stock Payment of exercise Dispose F No No 2.68 988 2.65K 10,199
10 Aug 22 Brum Lynne H Common Stock Payment of exercise Dispose F No No 2.68 864 2.32K 9,352
10 Aug 22 Peoples Oliver P Common Stock Payment of exercise Dispose F No No 2.68 5,286 14.17K 44,602
46.4% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 16 19 -15.8%
Opened positions 2 3 -33.3%
Closed positions 5 3 +66.7%
Increased positions 2 5 -60.0%
Reduced positions 3 3
13F shares Current Prev Q Change
Total value 25.6M 30.61M -16.3%
Total shares 2.28M 3M -24.1%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Schuler Jack W 1.7M $23.77M 0.0%
Cannell Peter B & Co 161.34K $363K 0.0%
Lind Global Macro Fund 150.68K $871K 0.0%
Vanguard 114.35K $257K -2.3%
Millennium Management 58.77K $132K NEW
Geode Capital Management 35.31K $79K 0.0%
BLK Blackrock 31.38K $71K -25.3%
Citadel Advisors 17.88K $40K NEW
UBS UBS Group AG - Registered Shares 5.36K $12K +69.5%
Concord Wealth Partners 3.5K $8K 0.0%
Largest transactions Shares Bought/sold Change
Hirschman Orin 0 -349.2K EXIT
AIGH Capital Management 0 -343.69K EXIT
Worth Venture Partners 0 -80.59K EXIT
Millennium Management 58.77K +58.77K NEW
Citadel Advisors 17.88K +17.88K NEW
Jane Street 0 -13.66K EXIT
BLK Blackrock 31.38K -10.63K -25.3%
Vanguard 114.35K -2.64K -2.3%
UBS UBS Group AG - Registered Shares 5.36K +2.2K +69.5%
Tower Research Capital 0 -1.11K EXIT

Financial report summary

?
Risks
  • We have a history of net losses and our future profitability is uncertain.
  • We will need to secure additional funding to finance our operations and may not be able to do so when necessary, and/or the terms of any financings may not be advantageous to us.
  • Our seed products and crop science technologies are at an early stage of development. We may never commercialize a technology or product that will generate meaningful, or any, revenues.
  • There can be no assurance that we will be able to comply with the continued listing standards of The Nasdaq Capital Market.
  • Currently, our primary source of our revenue is government research grants; continued availability of grant funding is uncertain and contingent on our compliance with the requirements of the grant.
  • Our government grants may subject us to government audits, which could expose us to penalties if we have failed to comply with the terms of the grants.
  • Our financial condition, research and development efforts, and results of operations could be further adversely affected by the ongoing coronavirus outbreak.
  • Our business operations could be adversely affected by the impact of the war in Ukraine.
  • Any potential collaborative partnerships that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our innovations.
  • Our crop science program may not be successful in developing commercial products.
  • Even if we or our future collaborators are successful in developing commercial products that incorporate our traits, such products may not achieve commercial success.
  • If ongoing or future field trials conducted by us or our future collaborators are unsuccessful, we may be unable to complete the regulatory process for, or commercialize, our products in development on a timely basis.
  • Adverse weather conditions, natural disasters, crop disease, pests and other natural conditions can impose significant costs and losses on our business.
  • Competition in the market for traits and seeds is intense and requires continuous technological development, and, if we are unable to compete effectively, our financial results will suffer.
  • If we or our future collaborators are unable to comply with and timely complete the regulatory process in the United States and Canada for our future products in development, our or our future collaborators’ ability to market our traits could be delayed, prevented or limited.
  • The regulatory environment for genetically engineered crops in jurisdictions outside the United States and Canada varies greatly, and some jurisdictions have more restrictive regulations that could delay, prevent or limit our or our future collaborators’ ability to market our traits.
  • Government policies and regulations, particularly those affecting the agricultural sector and related industries, could adversely affect our operations and our ability to generate future revenues and to achieve profitability.
  • The products of third parties, or the environment itself, may be negatively affected by the unintended appearance of our trait genes, novel seed compositions and novel seed products.
  • Loss of or damage to our elite novel trait events and plant lines would significantly slow our product development efforts.
  • Our insurance coverage may be inadequate to cover all the liabilities we may incur.
  • We rely on third parties to conduct, monitor, support, and oversee field trials and, in some cases, to maintain regulatory files for those products in development, and any performance issues by third parties, or our inability to engage third parties on acceptable terms, may impact our ability to complete the regulatory process for or commercialize such products.
  • If we lose key personnel or are unable to attract and retain necessary talent, we may be unable to develop or commercialize our products under development.
  • Our business and operations would suffer in the event of system failures.
  • Patent protection for our technologies is both important and uncertain.
  • Portions of our crop science technology are owned by or subject to retained rights of third parties.
  • We may not be successful in obtaining necessary rights to additional technologies for the development of our products through acquisitions and in-licenses.
  • Our license agreements include royalty payments that we are required to make to third parties.
  • The intellectual property landscape around genome editing technology, such as CRISPR, is highly dynamic and uncertain, and any resolution of this uncertainty could have a material adverse effect on our business.
  • We rely in part on trade secrets to protect our technology, and our failure to obtain or maintain trade secret protection could harm our business.
  • Raising additional funds may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies.
  • Trading volume in our stock can fluctuate and an active trading market for our common stock may not be available on a consistent basis to provide stockholders with adequate liquidity. Our stock price may be volatile, and our stockholders could lose a significant part of their investment.
  • Provisions in our certificate of incorporation and by-laws and Delaware law might discourage, delay or prevent a change of control of our company or changes in our management and, therefore, depress the trading price of our common stock.
  • Concentration of ownership among our officers, directors and principal stockholders may prevent other stockholders from influencing significant corporate decisions and depress our stock price.
Management Discussion
  • ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
  • This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements relate to our future plans, objectives, expectations and intentions and may be identified by words such as “may,” “will,” “should,” “expects,” “plans,” “anticipate,” “intends,” “target,” “projects,” “contemplates,” “believe,” “estimates,” “predicts,” “potential,” and “continue,” or similar words.
  • Although we believe that our expectations are based on reasonable assumptions within the limits of our knowledge of our business and operations, these forward-looking statements contained in this document are neither promises nor guarantees. Our business is subject to significant risk and uncertainties and there can be no assurance that our actual results will not differ materially from our expectations. These forward-looking statements include, but are not limited to, statements concerning our business plans and strategies; expected future financial results and cash requirements; statements related to the coronavirus pandemic and its potential adverse impacts; the impact from the war in Ukraine and the resulting economic and other sanctions imposed on Russia; plans for obtaining additional funding; plans and expectations that depend on our ability to continue as a going concern; and plans for development and commercialization of our Yield10 technologies. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated including, without limitation, risks related to our limited cash resources, uncertainty about our ability to secure additional funding, risks related to the execution of our business plans and strategies, risks associated with the protection and enforcement of our intellectual property rights, as well as other risks and uncertainties set forth under the caption "Risk Factors"

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: analogy, branding, Bureau, cleaning, conditioner, Consumer, difficult, fish, fuel, fulfill, grain, Harvest, harvested, Index, inflation, instance, inventory, labor, line, multiplication, network, offtake, packaging, ramp, shipped, slightly, storage, summer, supplemented, team, transparency, treatment, undertaken, Urban, variety, YOI
Removed: April, Argentina, classification, conducted, covering, earn, enhanced, manufacture, MOI, receive, trial